Ligand director Zimmermann proposes $636K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ligand Pharmaceuticals Inc. director Martine Zimmermann filed a notice covering a proposed sale of 2,000 common shares, with an aggregate market value of $636,336.20 and an approximate sale date of November 12, 2026. The notice lists 20,002,986 common shares outstanding. It also reports that Zimmermann sold 1,200 common shares on September 10, 2026, for gross proceeds of $342,000.00 during the preceding three months.
Key Figures
Key Terms
Restricted Stock financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.